Feb 14, 2023 / 01:00PM GMT
Tom Smith - SVB Securities LLC - Analyst
All right. Good morning, everyone. Thanks for joining us here at the SVB Securities Global Biopharma Conference. My name is Tom Smith. I'm a senior biotech analyst here at SVB Securities and very happy to be hosting our first panel here with Galecto. And joining us from the company, we have CEO, Hans Schambye. Hans, thanks for joining us.
Hans Schambye - Galecto, Inc. - CEO
Tom, thanks a lot for having us, always exciting. And I look forward to presenting and discussing.
Tom Smith - SVB Securities LLC - Analyst
Of course, likewise. Just one quick housekeeping note here for investors joining us on the webcast, feel free to submit any questions for Hans via the webcast portal or e-mail them to me directly at [email protected].
Hans, I know you have some slides you'd like to walk through and then maybe we can move into some Q&A.
Hans Schambye - Galecto, Inc. - CEO
Sure. Sounds good. Galecto is really working to
Galecto Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
